Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Drug Dosing: Geriatric Patients

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Just Pop It: Early AROM After Cervical Ripening Reduces the Time to Delivery.

Journal of the American Board of Family Medicine : JABFM·2024

Same author

A population-based study on the epidemiology of firearm-related injury in Nova Scotia.

Injury·2022

Same author

The effect of legislation on firearm-related deaths in Canada: a systematic review.

CMAJ open·2022

Same author

Mandatory gunshot wound reporting in Nova Scotia: a pre-post-evaluation of firearm-related injury rates.

CJEM·2022

Same author

PURL: Can viscous fiber lower glycemic markers in type 2 diabetes?

The Journal of family practice·2021

Same author

PURL: NPH insulin: It remains a good option.

The Journal of family practice·2020

Search research articles

Related Experiment Video

Updated: Dec 18, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

PURL: How old is too old for statins?

Bob Marshall¹, Nick Bennett¹

¹Madigan Family Medicine Residency, Tacoma, WA, USA.

The Journal of Family Practice

|June 20, 2020

Summary

Deciding whether to start, continue, or stop statin therapy in adults 75 years and older remains unclear. Two recent studies offer new insights into this complex clinical decision for older populations.

Area of Science:

Cardiology
Geriatrics
Pharmacology

Background:

Statins are widely prescribed cholesterol-lowering drugs.
Evidence for statin use in individuals aged 75 years and older is limited and conflicting.
Optimal management strategies for primary and secondary prevention in this age group are debated.

Purpose of the Study:

To evaluate the benefits and risks of initiating or continuing statin therapy in adults aged 75 years and older.
To provide evidence-based guidance on statin discontinuation in the elderly.
To address the clinical quandary surrounding statin use in geriatric populations.

Main Methods:

Review of two large-scale clinical studies.
Analysis of patient data focusing on cardiovascular outcomes, mortality, and adverse events.

More Related Videos

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Experiment Videos

Last Updated: Dec 18, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Stratification of results based on age, comorbidities, and prior statin use.

Main Results:

Study 1 found potential benefits of continuing statins in select elderly patients.
Study 2 suggested that stopping statins may not significantly increase risk in certain older adults.
Individualized risk-benefit assessments are crucial for treatment decisions.

Conclusions:

The decision to start, continue, or stop statins in individuals 75 years and older requires careful consideration of individual patient factors.
Further research is needed to refine guidelines for statin therapy in the oldest populations.
Personalized medicine approaches are essential for optimizing cardiovascular care in the elderly.